Differences in methods for determining SAMHD1 status, the heterogeneity of the clinical series evaluated, and the possible different treatments that patients receive may explain the apparent contradictory results between data from databases and our data, which rely on rather small but homogenous cohorts evaluated using the same criteria across tumor types and samples. The gene discussed is SAMHD1; the disease is neoplasm.